Toshi Biopharm Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-10-2024
- Paid Up Capital ₹ 0.10 M
as on 23-10-2024
- Company Age 10 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 22.79%
(FY 2023)
- Profit 57.66%
(FY 2023)
- Ebitda -1092.38%
(FY 2023)
- Net Worth 25.86%
(FY 2023)
- Total Assets -0.91%
(FY 2023)
About Toshi Biopharm
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anurag Sarswat, Kamaluddin Kakar, and Naresh Kumar serve as directors at the Company.
- CIN/LLPIN
U52100DL2014PTC271331
- Company No.
271331
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Sep 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Toshi Biopharm Private Limited offer?
Toshi Biopharm Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Malaria Medicine, Diabetes Medicine, Antifungal Injection, Tablet & Syrup, Itraconazole Capsule and Tablet.
Who are the key members and board of directors at Toshi Biopharm?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anurag Sarswat  | Director | 03-May-2016 | Current |
Kamaluddin Kakar  | Additional Director | 01-May-2019 | Current |
| Naresh Kumar | Additional Director | 05-Mar-2020 | Current |
Financial Performance of Toshi Biopharm.
Toshi Biopharm Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 22.79% increase. The company also saw a substantial improvement in profitability, with a 57.66% increase in profit. The company's net worth Soared by an impressive increase of 25.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Toshi Biopharm?
In 2023, Toshi Biopharm had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Toshi Biopharm?
Unlock and access historical data on people associated with Toshi Biopharm, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Toshi Biopharm, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Toshi Biopharm's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
